Disease index

chronic stable angina

Cardiovascular · 2007–2009

4decisions
1medicine
0carried consumer input
0individual submissions

Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.

Every decision

MedicineMeetingOutcomeConsumer input
ivabradine hydrochloride Treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm who are unable to tolerate or have a… Jul 2009 Recommended no section in document
ivabradine hydrochloride Treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm who are unable to tolerate or have a… Nov 2007 Recommended no section in document
ivabradine hydrochloride Treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm who are unable to tolerate or have a… Nov 2007 Recommended no section in document
ivabradine hydrochloride Treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm who are unable to tolerate or have a… Nov 2007 Recommended no section in document

What the PBS pays

$7M in government benefit over 2024–25, across 197,852 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
Ivabradine hydrochloride $3.5M
ivabradine hydrochloride $3.5M

Registered, not subsidised

Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.

MedicineOn the ARTG sinceRegistrations
diltiazemAPO-DILTIAZEM CD diltiazem hydrochloride 180mg capsules blisterpack 1993 22

The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.